Department of Nuclear Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.
Department of Urology, University Hospital Muenster, Muenster, Germany.
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246. doi: 10.1007/s00259-017-3877-z. Epub 2017 Nov 13.
Radioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated patients with metastatic castration resistant prostate cancer. The aim of this retrospective study was to analyze response in patients receiving 3 cycles of Lu-PSMA.
Seventy-one patients (median age: 72 years; range 44-87) received 3 cycles of RLT with Lu-PSMA (mean administered activity: 6.016 ± 0.543 GBq) every 8 weeks. Response was evaluated using serum PSA levels and a PSA decline ≥50% was considered as biochemical response. Additionally, any PSA decline after the first cycle was evaluated for further therapy effects after the second and third cycle.
A total of 213 cycles were performed in 71 patients. Data for response and adverse events were available for all patients. A PSA decline ≥50% and some PSA decline occurred in 56% and 66% of the patients. Of 30 patients with a PSA response after the first cycle, 28 remained responders and 12/41 of non-responders responded to further therapy cycles.
RLT with Lu-177-PSMA-617 shows respectable response rates. In this retrospective analysis, a relevant number of patients showed a delayed response, even if they did not respond to the first cycle of the therapy.
使用镥-177 标记的 PSMA-617（Lu-PSMA）配体的放射性配体治疗（RLT）是一种新的治疗选择，用于挽救治疗经过大量预处理的转移性去势抵抗性前列腺癌患者。本回顾性研究的目的是分析接受 3 个周期 Lu-PSMA 治疗的患者的反应。
71 名患者（中位年龄：72 岁；范围 44-87 岁）每 8 周接受 3 个周期的 Lu-PSMA（平均给予活性：6.016±0.543GBq）RLT。使用血清 PSA 水平评估反应，PSA 下降≥50%被认为是生化反应。此外，在第二个和第三个周期后，还评估了第一个周期后任何 PSA 下降的进一步治疗效果。
71 名患者共进行了 213 个周期。所有患者均有反应和不良事件的数据。56%和 66%的患者出现 PSA 下降≥50%和某些 PSA 下降。在第一个周期后 PSA 有反应的 30 名患者中，28 名仍为有反应者，41 名无反应者中有 12 名对进一步治疗周期有反应。
Lu-177-PSMA-617 的 RLT 显示出可观的反应率。在这项回顾性分析中，即使患者对治疗的第一个周期没有反应，仍有相当数量的患者出现延迟反应。
